Application of Streptococcus agalactiae in treatment of endometriosis

The invention belongs to the technical field of biology, and identifies that the fixed value of streptococcus agalactiae of streptococcus is abnormally increased in the cervix uteri of an endometriosis patient through sequencing. Through clinical samples and construction of an endometriosis mouse model, research finds that streptococcus agalactiae regulates Ang-2 to promote angiogenesis, and thenthe valuation and invasion capacity of ectopic tissues in an abdominal cavity are enhanced. After teicoplanin is added to inhibit streptococcus agalactiae, the number and the size of endometriosis lesions in the abdominal cavity of the endometriosis mouse model are obviously inhibited, so that a new way for treating endometriosis is confirmed, and a new strategy is provided for treatment of endometriosis. 本发明属于生物技术领域，通过测序鉴定出链球菌属的无乳链球菌在子宫内膜异位症患者宫颈口定值异常增多。通过临床样本和构建子宫内膜异位症小鼠模型，研究发现无乳链球菌调控Ang-2促进血管生成，进而加强了异位组织在腹腔的定值和侵袭能力。而加入替考拉宁抑制无乳链球菌后，子宫内膜异位症小鼠模型腹腔中异位症病灶的数量和大小受到明显抑制，从而确认了一个治疗子宫内膜异位症的新途径，为子宫内膜异位症的治疗提供新策略。